CELLforCURE manufacturing partner of Cellectis for the manufacture of UCART123

On 15th November 2016, Cellectis, a biopharmaceutical company specialising in the development of immunotherapies based on engineered CAR-T cells (UCART), announced the first large-scale manufacturing of a series of batches for UCART123, in compliance with Good Manufacturing Practices (GMP).


In its press release, Cellectis states that “the manufacturing process for Cellectis’ allogeneic CAR T-cell product line, Universal CARTs or UCARTs, yields frozen, off-the-shelf, engineered CAR T-cells. UCARTs are meant to be readily available CAR T-cells for a large patient population. Their production can be industrialized and standardized with defined pharmaceutical release criteria.”


CELLforCURE, an LFB group company, manufactures Cellectis’ UCART123 in its industrial facility of Les Ulis (France).


Read Cellectis’ press release by clicking here : http://www.cellectis.com/en/content/cellectis-announces-successful-cgmp-manufacturing-second-product-candidate-ucart123-0